Nanjing Legend Biotech Co.

This early study tests a new treatment called LUCAR-DKS1 in 36 adults with autoimmune diseases that have not responded to standard therapies. The treatment uses specially designed immune cells to target and control the overactive immune system. The main goals are to check safety …

This study is testing an experimental cell therapy called LCAR-F33S in 35 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see how well the therapy works against the cancer. Pa…

This study tests a new treatment called LUCAR-G79 for people with autoimmune diseases like lupus that have not improved with standard care. The treatment uses specially modified cells to target and attack faulty immune cells. The main goals are to check safety and find the best d…

This early-stage study tests a new treatment called LUCAR-G79D for adults with lupus or inflammatory myopathies that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack disease-causing cells. The main goals are …